Search

Your search keyword '"123I-FP-CIT"' showing total 123 results

Search Constraints

Start Over You searched for: Descriptor "123I-FP-CIT" Remove constraint Descriptor: "123I-FP-CIT" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
123 results on '"123I-FP-CIT"'

Search Results

1. Comparison of the ability of different quantitative indices in 123I-FP-CIT single-photon emission computed tomography to differentiate dopaminergic neurodegenerative disease.

2. Clinical assessment and striatal dopaminergic activity in healthy controls and patients with Parkinson's disease: a Bayesian approach.

4. Verification of optimal conditions for the scattering correction of 123I-FP-CIT SPECT on a single-photon emission tomography system with a two-detector whole-body cadmium–zinc–telluride semiconductor detector.

6. Association between longitudinal changes in striatal dopamine transporter uptake and clinical features of dementia with Lewy bodies.

7. Effect of cerebrospinal fluid area mask correction on 123I-FP-CIT SPECT images in idiopathic normal pressure hydrocephalus

8. No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome.

10. Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson's Disease: A Multicenter Study.

11. Effect of cerebrospinal fluid area mask correction on 123I-FP-CIT SPECT images in idiopathic normal pressure hydrocephalus.

13. Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases.

14. Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123I-Ioflupane SPECT: an investigation of parkinsonian syndromes

15. Multi-Atlas MRI-Based Striatum Segmentation for 123I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome

16. A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis.

17. Case Report: The Role of Neuropsychological Assessment and Imaging Biomarkers in the Early Diagnosis of Lewy Body Dementia in a Patient With Major Depression and Prolonged Alcohol and Benzodiazepine Dependence

18. Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings

19. Effect of sex on aging-related decline of dopamine transporter in healthy subjects.

20. Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease.

21. Case Report: The Role of Neuropsychological Assessment and Imaging Biomarkers in the Early Diagnosis of Lewy Body Dementia in a Patient With Major Depression and Prolonged Alcohol and Benzodiazepine Dependence.

22. MRI-guided voxel-based automatic semi-quantification of dopamine transporter imaging.

23. Continuous Repetitive Data Acquisition with 123I-FP-CIT SPECT: Effects of Rotation Speed and Rotation Time.

24. The utility of the combined use of 123I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes.

25. Head‐to‐head comparison of 18F‐FP‐CIT and 123I‐FP‐CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study.

26. The Utility of the Combined Use of 123I-FP-CIT and 123I-MIBG Myocardial Scintigraphy in Differentiating Parkinson's Disease from Other Parkinsonian Syndromes.

27. Quantitative evaluation of the tracer distribution in dopamine transporter SPECT for objective interpretation.

28. Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count.

29. The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia

30. The effect of scatter correction and radius of rotation on semiquantitative measurements in SPECT 123I-FP-CIT imaging. A phantom study

31. Semiquantitative analysis using standardized uptake value in 123I-FP-CIT SPECT/CT

32. Impact of quantitative index derived from 123I-FP-CIT-SPECT on reconstruction with correction methods evaluated using a 3D-striatum digital brain phantom

33. The Utility of the Combined Use of 123I-FP-CIT and 123I-MIBG Myocardial Scintigraphy in Differentiating Parkinson’s Disease from Other Parkinsonian Syndromes

34. Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT

35. Determination of the biodistribution and dosimetry of 123I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging.

36. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.

37. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias.

38. Interobserver variability, and visual and quantitative parameters of I-FP-CIT SPECT (DaTSCAN) studies.

39. Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies

40. Pupillometry and 123I-DaTSCAN imaging in Parkinson's Disease: A Comparison Study.

41. SPECT imaging evaluation in movement disorders: far beyond visual assessment.

42. Clinicopathological and 123 I-FP-CIT SPECT correlations in patients with dementia

43. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study.

44. A Cavalier King Charles dog with shadow chasing: Clinical recovery and normalization of the dopamine transporter binding after clomipramine treatment.

45. The impact of reconstruction method on the quantification of DaTSCAN images.

48. Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson’s disease patients.

49. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.

50. New semiquantitative assessment of123I-FP-CIT by an anatomical standardization method.

Catalog

Books, media, physical & digital resources